Press Release

<< Back
View printer-friendly version

Spark Therapeutics Announces Closing of Its Initial Public Offering

PHILADELPHIA, Feb. 4, 2015 /PRNewswire/ -- Spark Therapeutics (NASDAQ: ONCE) announced today the closing of its initial public offering of 8,050,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts, including 1,050,000 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price. All of the shares in the offering were sold by Spark.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as lead book-running managers for the offering.  Cowen and Company, LLC acted as lead manager and Sanford C. Bernstein & Co., LLC acted as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 29, 2015. Copies of the final prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by telephone at +1 (800) 221-1037, or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Spark Therapeutics     

Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases.  Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition.  Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases.


To view the original version on PR Newswire, visit:

SOURCE Spark Therapeutics

Stephen Webster, 215-220-9327